Avita Medical Ltd., of Melbourne, Australia, said the Federal Court of Australia has approved its proposed redomiciliation to the U.S., whereby Avita Therapeutics Inc. will become the parent company of the Avita Group. The company’s shares will be suspended from trading on the ASX from close of trading on June 23, 2020.
Montreal-based Caprion-Histogenex is partnering with Clinical Logistics Inc., a virtual central laboratory located in Dartmouth, Nova Scotia, to offer COVID-19 polymerase chain reaction (PCR) testing services. The company is providing testing via the Taqpath COVID-19 Multiplex RT-PCR test from Thermo Fisher Scientific Inc., of Waltham, Mass.
Gendius Ltd., of Macclesfield, U.K., is partnering with Astrazeneca plc, of Cambridge, U.K., to improve diabetes management support in the Gulf region using Gendius’ Intellin platform. The partnership is being implemented as part of Astrazeneca’s Emerging Markets Health Innovation Hubs initiative.
North Billerica, Mass.-based Lantheus Holdings Inc., the parent company of Lantheus Medical Imaging Inc., has completed its merger with Progenics Pharmaceuticals Inc., of Tarrytown, N.Y. For each share of Progenics common stock, Progenics shareholders received 0.31 of a share of Lantheus common stock and one nontradeable contingent value right, payable in two contingent payments, subject to a cap, upon the achievement of certain milestones related to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen targeted imaging agent for visualization of prostate cancer. Lantheus will continue to trade on Nasdaq under the LNTH symbol. Progenics was delisted.
Mevion Medical Systems Inc., of Littleton, Mass., and Orfit Industries NV, of Wijnegem, Belgium, reported that Orfit’s Aerial Couch Top is validated for use on the Mevion S250 Series Proton Therapy Systems.
Vancouver, British Columbia-based Microdermics Inc. is seeking M&A or technology out-licensing opportunities to commercialize its microneedle drug delivery and biosensing technology. The company has retained Novateur Ventures Inc., of Vancouver, to lead the transaction process.
Natera Inc., of San Carlos, Calif., has expanded its Austin, Texas, laboratory capacity with a new 70,000-square-foot facility.
National Jewish Health, of Denver, reported the availability of an additional test to detect SARS-CoV-2, the virus that causes COVID-19. The hospital developed the assay in collaboration with Agena Bioscience Inc., of San Diego, to run on Agena’s Massarray system.
Houston-based Nuprobe Inc. and Weigao Group, of Weihai, Shandong, China, have teamed up to apply Nuprobe’s blocker displacement amplification technology to develop a liquid biopsy next-generation sequencing (NGS) panel for non-small-cell lung cancer. The product will be compatible with desktop NGS instruments, and the companies plan to apply for in vitro diagnostic registration with China’s National Medical Products Administration.
Salt Lake City-based Qaultrics LLC has released a contact tracing solution to help state and local governments control the spread of COVID-19. Built on Qualtrics’ Xm Platform, the tool automatically notifies impacted individuals and instructs them on next step safety measures, while maintaining confidentiality.